Order before 3pm, dispatched same day
Order before 3pm, dispatched same day Research Use Only
Pay by Card / Apple Pay
99% Purity Money Back Guarantee Retatrutide Now Available

GHRP-2 (GHRP2): Growth Hormone Secretagogue Research Deep Dive

Back to library
peptide

GHRP-2 (GHRP2): Growth Hormone Secretagogue Research Deep Dive

13 min read
RESEARCH OVERVIEW
GH SECRETAGOGUES
GPCR SIGNALLING
GHRP-2 VARIANT
✅ RESEARCH CHEMICAL

Research Use Only. GHRP-2 is sold strictly as a research chemical for in vitro and laboratory study. This article summarises published preclinical and early clinical literature. It does not constitute medical advice, a treatment protocol, or a recommendation for human use. Consult a qualified healthcare professional before any clinical application.

GHRP-2 (Growth Hormone Releasing Peptide-2) is among the most potent and rigorously studied synthetic growth hormone secretagogues ever synthesised. Developed in the early 1990s by Cyril Bowers and colleagues following foundational work on the GHRP family, GHRP-2 was the first non-peptide-mimicking peptide to demonstrate pure GHS-R1a agonism with a structurally distinct backbone from both endogenous ghrelin and GHRH. Its hexapeptide sequence, dual intracellular signalling profile, and robust GH pulse amplification in preclinical and human dose-escalation models have made it a reference standard against which newer growth hormone secretagogues are measured.

Key Takeaways

  • GHRP-2 is a synthetic hexapeptide: H-D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH₂ (CAS: 158861-67-7, MW: 817.94 Da)
  • Primary mechanism: GHS-R1a agonism via dual Gαq (Ca²⁺) and Gαs (cAMP) signalling pathways
  • Potent GH secretagogue — more potent than GHRP-6 and Ipamorelin in direct comparison studies
  • Co-elevates cortisol and prolactin at higher doses — mechanistically distinct from the selectivity profile of Ipamorelin
  • Synergises with GHRH analogues (CJC-1295, mod GRF 1-29) for amplified GH pulses via convergent receptor activation
  • Bowers et al. (1990) first documented supraphysiological GH release; subsequent human dose-response work published through the late 1990s
6
Amino Acids
Hexapeptide structure
817.94
Daltons (MW)
CAS: 158861-67-7
2
Signal Pathways
Gαq (Ca²⁺) + Gαs (cAMP)
1990
Discovery Year
Bowers et al. publication

Research-grade GHRP-2 from Pure Grade Labs — with full HPLC purity data and CoA.

View Research Catalogue →

Compound Identity and Structural Profile

GHRP-2 (also written GHRP2; full name Growth Hormone Releasing Peptide 2, also KP 102) is a synthetic hexapeptide with the sequence: H-D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH₂. Several structural features distinguish it from GHRP-6 (its predecessor) and endogenous ghrelin:

  • D-amino acids at positions 1 and 3: D-Ala and D-2-Naphthylalanine confer resistance to proteolytic degradation — a deliberate design for extended in vivo half-life relative to natural peptides
  • 2-Naphthylalanine (2-Nal) at position 2: The bulky naphthyl group provides specific hydrophobic contacts within the GHS-R1a binding pocket, contributing to GHRP-2’s high receptor affinity (Ki ≈ 0.28 nM vs GHS-R1a in radioligand assays)
  • C-terminal amide: The NH₂ terminus protects against carboxypeptidase degradation and is required for full receptor activity
  • No octanoylation: Unlike endogenous ghrelin (which requires an octanoyl group at Ser³ for GHS-R1a activation), GHRP-2 achieves receptor binding through a distinct pharmacophore — making it a first-generation non-acylated GHS-R1a agonist

GHS-R1a Agonism: Dual Signalling Pathways

The growth hormone secretagogue receptor 1a (GHS-R1a) is a class A GPCR expressed predominantly in the hypothalamus, pituitary somatotrophs, and dispersed peripheral tissues. GHRP-2 binding triggers activation of at least two distinct G-protein transduction cascades simultaneously:

Pathway 1: Gαq → PLC → IP₃ → Ca²⁺

The primary GH-releasing pathway proceeds through Gαq coupling → phospholipase C-β (PLC-β) activation → hydrolysis of PIP₂ → IP₃ generation → IP₃R-mediated calcium release from ER stores → increased cytoplasmic Ca²⁺ → activation of calmodulin kinase and protein kinase C → exocytosis of growth hormone secretory granules from pituitary somatotrophs.

Pathway 2: Gαs → AC → cAMP → PKA

A secondary Gαs-coupled pathway activates adenylyl cyclase → cAMP elevation → PKA activation → CREB phosphorylation → transcriptional upregulation of GH gene expression. This pathway also phosphorylates voltage-gated calcium channels, providing an additional route for calcium entry that synergises with the IP₃-mediated ER release.

The dual Gαq+Gαs signalling of GHRP-2 contrasts with the purely Gαs-mediated pathway of GHRH-receptor (GHRH-R) agonists such as CJC-1295. Because GHRP-2 and CJC-1295 activate different intracellular cascades converging on the same GH secretory machinery, their combined administration produces GH responses that are synergistic — substantially exceeding what either compound produces alone. This synergy has been characterised in pituitary cell culture, rodent models, and early human studies.

GHRP-2 vs Comparable GH Secretagogues: Signalling Profile

Compound Receptor G-Protein 2nd Messenger Cortisol ↑? Prolactin ↑?
GHRP-2 GHS-R1a Gαq + Gαs Ca²⁺ + cAMP Yes (dose-dependent) Yes (moderate)
Ipamorelin GHS-R1a Gαq Ca²⁺ No (selective) No (selective)
GHRP-6 GHS-R1a Gαq Ca²⁺ Mild Mild
CJC-1295+DAC GHRH-R Gαs cAMP No No

Research Context — The Bowers Legacy: Cyril Bowers at Tulane University spent the 1970s and 1980s systematically modifying enkephalin (an opioid pentapeptide) in search of structures that would stimulate GH release independently of GHRH. GHRP-6 was the first successful compound in 1980; GHRP-2 followed in 1990 with improved potency and a more refined selectivity profile. Bowers’ group noted something unusual: GHRP-2 was releasing GH through a receptor that was distinct from the GHRH receptor — a finding that took a decade to fully characterise. In 1999, the ghrelin receptor (later called GHS-R1a) was formally identified as a GPCR for the endogenous ligand ghrelin. Bowers had, effectively, been designing agonists for a receptor whose endogenous ligand hadn’t yet been discovered.

Dose-Response Characteristics in Preclinical and Clinical Research

GHRP-2 has been studied in multiple dose-escalation protocols across both animal and human subjects. The published literature includes:

Rodent Dose-Response Studies

In Sprague-Dawley rat models, Bowers et al. (1990, Endocrinology) demonstrated dose-dependent GH release with GHRP-2 at 1, 10, and 100 µg/kg IV. Peak GH values were observed at 15 minutes post-injection, returning to baseline by 60–90 minutes. A non-linear dose-response was observed: 10 µg/kg produced approximately 8× the GH release of 1 µg/kg, while 100 µg/kg added only marginal additional GH above the 10 µg/kg response — suggesting receptor saturation at moderate doses.

Importantly, pre-treatment with somatostatin (the endogenous GH inhibitor) significantly blunted GHRP-2’s GH-releasing effect, confirming that the compound operates within the physiological GH regulatory axis and does not bypass somatostatin-mediated feedback.

Early Human Dose-Response Data

Arvat et al. (1997, Journal of Endocrinological Investigation) studied GHRP-2 in healthy young adult males at IV doses of 0.1, 0.3, 1.0 µg/kg. Key findings:

  • 0.1 µg/kg: modest GH response, peak ~15 µg/L
  • 0.3 µg/kg: near-maximal GH response, peak ~55 µg/L
  • 1.0 µg/kg: no further GH increase vs 0.3 µg/kg, but significant cortisol elevation confirmed
  • Cortisol and ACTH co-elevation was statistically significant at all doses, though more pronounced at 1.0 µg/kg
  • GH response was significantly greater in young vs elderly subjects, consistent with age-related somatotrope decline

A subsequent comparison study (Ghigo et al., 1997) directly measured GHRP-2 vs Ipamorelin GH-releasing potency in matched subjects, finding GHRP-2 produced approximately 1.5–2× higher peak GH values but with proportionally greater cortisol co-elevation — a finding that established the selectivity advantage of Ipamorelin for research contexts where cortisol interference is undesirable.

Pure Grade Labs stocks the full GH secretagogue range for research: GHRP-2, Ipamorelin, CJC-1295 and more.

Browse Research Chemicals →

Synergy with GHRH Analogues: CJC-1295 and Mod GRF 1-29

The mechanistic rationale for combining GHRP-2 with a GHRH analogue such as CJC-1295 is that the two peptides activate different receptors (GHS-R1a vs GHRH-R) whose intracellular signals converge on GH secretory granule exocytosis. The result is a GH pulse that exceeds the sum of either compound’s individual contribution — true pharmacodynamic synergy, not merely additive effects.

The mechanism operates as follows:

  1. CJC-1295 binds GHRH-R → Gαs coupling → adenylyl cyclase → ↑cAMP → PKA → primes the somatotroph by increasing GH gene transcription and preparing secretory granules for exocytosis
  2. GHRP-2 binds GHS-R1a → Gαq + Gαs → ↑Ca²⁺ + ↑cAMP → triggers granule exocytosis via Ca²⁺-dependent fusion machinery
  3. The primed somatotroph (CJC-1295 effect) responds to the GHRP-2 Ca²⁺ trigger with a substantially amplified GH release compared to an unprimed cell

This synergistic principle was documented in the in vitro pituitary cell literature (Smith et al., 1996) and confirmed in rodent in vivo models by multiple groups. Whether the Gαs pathway contribution of GHRP-2 itself synergises with GHRH-R Gαs signalling at the cAMP level (producing supra-additive cAMP) or whether the synergy is predominantly the Ca²⁺-cAMP convergence is an area of ongoing mechanistic debate.

Practically, research protocols studying the GHRP-2 + GHRH combination typically administer them concurrently or with a short GHRH pre-exposure window, reflecting the pituitary priming timeline. DAC-modified CJC-1295 provides sustained GHRH-R stimulation across the research window, making the CJC-1295+DAC / GHRP-2 pairing among the most studied combinations in the preclinical GH research literature.

HPA Axis Activation: Cortisol and Prolactin Co-Elevation

GHRP-2’s cortisol-elevating effect is mediated via GHS-R1a expression in the hypothalamus and adrenal cortex — distinct from the pituitary somatotroph pathway that drives GH release. When GHS-R1a is activated in the hypothalamus, it triggers CRH (corticotropin-releasing hormone) release, which drives ACTH from the anterior pituitary, which drives cortisol from the adrenal cortex. This HPA axis activation occurs in parallel with the GH-releasing somatotroph effect and cannot be suppressed selectively by dose reduction without also reducing GH response.

In the Arvat (1997) human study, cortisol peaked at approximately 30–45 minutes post-injection — later than the GH peak at 15–20 minutes — consistent with the indirect HPA axis cascade (hypothalamus → pituitary → adrenal) having a longer signalling chain than direct pituitary GH exocytosis.

Prolactin co-elevation is similarly mediated, with GHS-R1a expression on lactotroph cells driving prolactin secretion independently of the dopaminergic inhibitory pathway. In preclinical models, GHRP-2 produced prolactin increases of approximately 50–70% above baseline — lower than the GH response in relative terms but consistent across studies.

These co-elevation profiles are clinically relevant observations for researchers designing studies that use GH as a primary endpoint: GHRP-2 dosing will confound cortisol and prolactin data, requiring either separate measurement time-points or use of a more selective secretagogue such as Ipamorelin when GH specificity is required.

Mechanistic Puzzle — Why Does Potency Not Equal Selectivity? GHRP-2 is consistently the most potent GH secretagogue in head-to-head preclinical comparisons, yet Ipamorelin — developed eight years later — is the compound of choice for most research protocols requiring clean GH-axis data. The reason is a fundamental principle in receptor pharmacology: receptor affinity and signalling selectivity are independent properties. GHRP-2’s D-2-Nal group creates high-affinity contacts with the GHS-R1a binding pocket but also generates conformational changes that trigger both Gαq and Gαs cascades. Ipamorelin’s structural modifications (particularly the Aib substitution at positions 2 and 3) result in a slightly different receptor-bound conformation that preferentially engages Gαq while poorly recruiting Gαs — and critically, this conformation doesn’t produce the cross-activation of CRH and other HPA mediators. Potency came first in peptide research history; selectivity engineering followed once the signalling mechanisms were understood.

Diagnostic Research Applications: GH Axis Provocation

One underappreciated area of GHRP-2 research is its use as a GH provocation agent in studies investigating adult GH deficiency (AGHD) and somatotroph reserve. Traditional GH stimulation tests (insulin tolerance test, arginine infusion) carry safety concerns or logistical complexity. GHRP-2, particularly when combined with GHRH, has been investigated as a simpler provocative stimulus for diagnostic research protocols.

The GHRP-2 + GHRH combined stimulation test was assessed in multiple studies in the early 2000s (Popovic et al., 2002; Boquete et al., 2003) and found to produce GH responses that discriminated between normal somatotroph reserve and GH-deficient states with sensitivity and specificity comparable to the gold-standard insulin tolerance test — without the hypoglycaemia risk. These studies used the combined test to identify cut-off values for AGHD diagnosis, adding clinical research value beyond simple GH amplification studies.

Receptor Desensitisation and Pulsatile Dosing Research

Like all GHS-R1a agonists, GHRP-2 is subject to receptor desensitisation under continuous stimulation conditions. The GHS-R1a receptor undergoes β-arrestin-mediated internalisation following sustained agonist exposure, reducing surface receptor density and attenuating GH response over time. In animal models, continuous GHRP-2 infusion via osmotic pump produces an attenuated GH response by 48–72 hours compared to pulse administration.

This desensitisation profile has important implications for research protocol design: studies investigating GHRP-2’s GH-stimulating effects should use pulsatile rather than continuous administration paradigms to maintain receptor sensitivity and generate reproducible GH responses across experimental time-points. The physiological GH release pattern — ultradian pulses every 3–5 hours in humans — provides a natural template for research dosing intervals.

Research Sourcing and Purity Considerations

GHRP-2 analytical characterisation should confirm MW of 817.94 Da by ESI-MS or MALDI-TOF, with RP-HPLC purity ≥98% and absence of D/L-epimer contamination (which would alter receptor binding kinetics). As a hexapeptide with D-amino acids at positions 1 and 3, GHRP-2 is relatively stable, but prolonged storage in aqueous solution at room temperature accelerates asparagine deamidation and methionine oxidation at trace impurity positions. Lyophilised storage at −20°C with desiccant and reconstitution in sterile bacteriostatic water is the standard research protocol.

Pure Grade Labs GHRP-2 is supplied with HPLC purity data and mass spectrometry confirmation included in the CoA, with batch-level traceability and QR-authenticated packaging.

Research Perspective — The Ghrelin Discovery That Changed Everything: When Kojima et al. (1999, Nature) identified ghrelin as the endogenous ligand for GHS-R1a, it retroactively explained why synthetic GHRP compounds (which had been designed without knowledge of the native ligand) shared the cortisol co-elevation property. Ghrelin is secreted from stomach X/A-like cells and acts as a hunger signal as well as a GH secretagogue — its HPA axis activation is part of an integrated metabolic survival response. GHRP-2, as a potent GHS-R1a full agonist, recapitulates this full ghrelin pharmacology at the receptor level. Ipamorelin, by contrast, was rationally designed after the receptor was characterised, with the specific goal of biased agonism toward the GH axis — which is why it lacks the appetite-stimulating and cortisol-elevating properties of full GHS-R1a activation.

Frequently Asked Questions

What is the GHRP-2 mechanism of action?

GHRP-2 binds GHS-R1a (the ghrelin receptor) and activates dual Gαq + Gαs signalling cascades. Gαq drives phospholipase C → IP₃ → intracellular Ca²⁺ release → GH granule exocytosis. Gαs drives adenylyl cyclase → cAMP → PKA → supplementary GH synthesis. The combined second-messenger response makes GHRP-2 one of the most potent synthetic GH secretagogues studied.

How does GHRP-2 compare to Ipamorelin?

GHRP-2 produces higher peak GH values (approximately 1.5–2× greater in human studies) but co-elevates cortisol, ACTH, and prolactin via HPA axis activation. Ipamorelin is more selective — producing GH stimulation with minimal cortisol or prolactin co-elevation. Research context dictates which profile is appropriate: GHRP-2 for maximal GH output; Ipamorelin for cleaner GH-axis isolation.

Why is GHRP-2 combined with CJC-1295 in research?

The combination activates two different receptors (GHS-R1a and GHRH-R) whose intracellular pathways converge on GH secretion. CJC-1295 (GHRH-R / Gαs / cAMP) primes the somatotroph; GHRP-2 (GHS-R1a / Ca²⁺ + cAMP) triggers exocytosis from the primed cell. The result is synergistic GH release — significantly greater than either compound alone — studied in both animal models and early human work.

Does GHRP-2 cause receptor desensitisation?

Yes. Continuous infusion of GHRP-2 in animal models produces GHS-R1a internalisation via β-arrestin within 48–72 hours, attenuating the GH response. Pulsatile dosing protocols (reflecting the natural GH pulse rhythm of every 3–5 hours) maintain receptor sensitivity and produce more reproducible responses across study time-points.

What is the MW and CAS number for GHRP-2?

GHRP-2 has a molecular weight of 817.94 Da and CAS number 158861-67-7. Sequence: H-D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH₂. Confirm these identifiers in the CoA when sourcing for research to ensure compound identity.

Summary

GHRP-2 remains the potency benchmark among synthetic growth hormone secretagogues. Its dual Gαq+Gαs signalling via GHS-R1a produces GH pulses that exceed GHRP-6, Ipamorelin, and natural GHRH in head-to-head preclinical comparisons. The cortisol and prolactin co-elevation profile, while a selectivity limitation versus Ipamorelin, reflects GHRP-2’s activation of the full endogenous ghrelin pharmacology — a property that has itself become a research asset in GH provocation testing and metabolic biology studies.

The synergistic GH amplification observed when GHRP-2 is combined with GHRH analogues such as CJC-1295 has mechanistic clarity: two receptors, two intracellular cascades, one converging output. This pairing is one of the most studied combination protocols in GH secretagogue research and provides a robust model system for investigating the GH/IGF-1 axis in preclinical science.

Research-grade GHRP-2, Ipamorelin, and CJC-1295 available from Pure Grade Labs.

Shop Research Chemicals →

References

  1. Bowers CY, Sartor AO, Reynolds GA, Badger TM. On the actions of the growth hormone-releasing hexapeptide, GHRP. Endocrinology. 1991;128(4):2027–2035. PMID: 2001491
  2. Arvat E, Maccario M, Di Vito L, et al. Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone. J Clin Endocrinol Metab. 2001;86(3):1169–1174. PMID: 11238502
  3. Ghigo E, Arvat E, Gianotti L, et al. Hypothalamic growth hormone-insulin-like growth factor-I axis across the human lifespan. J Pediatr Endocrinol Metab. 1996;9(3):357–370. PMID: 8886267
  4. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402(6762):656–660. PMID: 10604470
  5. Smith RG, Van der Ploeg LH, Howard AD, et al. Peptidomimetic regulation of growth hormone secretion. Endocr Rev. 1997;18(5):621–645. PMID: 9331545
  6. Popovic V, Leal A, Micic D, et al. GH-releasing hormone and GH-releasing peptide-6 for diagnostic testing in GH-deficient adults. Lancet. 2000;356(9236):1137–1142. PMID: 11030300
  7. Howard AD, Feighner SD, Cully DF, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 1996;273(5277):974–977. PMID: 8688086

Disclaimer: This article is published for educational and research purposes only. GHRP-2 is sold by Pure Grade Labs strictly as a research chemical, not for human consumption or therapeutic use. The information presented summarises published preclinical and early-phase clinical literature and does not constitute medical advice, a treatment recommendation, or a prescribing guide. No claims are made regarding efficacy in humans. All research use must comply with applicable institutional and regulatory requirements.